The Swiss pharma has set up its challenge to AbbVie’s blockbuster immunosuppressive drug Humira with a label expansion for Cosentyx in hidradenitis suppurativa, a painful long-term skin condition.
https://www.pharmalive.com/wp-content/uploads/2023/09/Novartis-California.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-11-02 09:00:512023-11-02 09:10:35Novartis adds hidradenitis suppurativa to Cosentyx’s label in challenge to Humira
